Cargando…
Patient-Derived Cancer Organoids for Precision Oncology Treatment
The emergence of three-dimensional human organoids has opened the door for the development of patient-derived cancer organoid (PDO) models, which closely recapitulate parental tumor tissue. The mainstays of preclinical cancer modeling include in vitro cell lines and patient-derived xenografts, but t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156513/ https://www.ncbi.nlm.nih.gov/pubmed/34067714 http://dx.doi.org/10.3390/jpm11050423 |
_version_ | 1783699462751780864 |
---|---|
author | Pernik, Mark N. Bird, Cylaina E. Traylor, Jeffrey I. Shi, Diana D. Richardson, Timothy E. McBrayer, Samuel K. Abdullah, Kalil G. |
author_facet | Pernik, Mark N. Bird, Cylaina E. Traylor, Jeffrey I. Shi, Diana D. Richardson, Timothy E. McBrayer, Samuel K. Abdullah, Kalil G. |
author_sort | Pernik, Mark N. |
collection | PubMed |
description | The emergence of three-dimensional human organoids has opened the door for the development of patient-derived cancer organoid (PDO) models, which closely recapitulate parental tumor tissue. The mainstays of preclinical cancer modeling include in vitro cell lines and patient-derived xenografts, but these models lack the cellular heterogeneity seen in human tumors. Moreover, xenograft establishment is resource and time intensive, rendering these models difficult to use to inform clinical trials and decisions. PDOs, however, can be created efficiently and retain tumor-specific properties such as cellular heterogeneity, cell–cell and cell–stroma interactions, the tumor microenvironment, and therapeutic responsiveness. PDO models and drug-screening protocols have been described for several solid tumors and, more recently, for gliomas. Since PDOs can be developed in clinically relevant time frames and share many characteristics of parent tumors, they may enhance the ability to provide precision oncologic care for patients. This review explores the current literature on cancer organoids, highlighting the history of PDO development, organoid models of glioma, and potential clinical applications of PDOs. |
format | Online Article Text |
id | pubmed-8156513 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81565132021-05-28 Patient-Derived Cancer Organoids for Precision Oncology Treatment Pernik, Mark N. Bird, Cylaina E. Traylor, Jeffrey I. Shi, Diana D. Richardson, Timothy E. McBrayer, Samuel K. Abdullah, Kalil G. J Pers Med Review The emergence of three-dimensional human organoids has opened the door for the development of patient-derived cancer organoid (PDO) models, which closely recapitulate parental tumor tissue. The mainstays of preclinical cancer modeling include in vitro cell lines and patient-derived xenografts, but these models lack the cellular heterogeneity seen in human tumors. Moreover, xenograft establishment is resource and time intensive, rendering these models difficult to use to inform clinical trials and decisions. PDOs, however, can be created efficiently and retain tumor-specific properties such as cellular heterogeneity, cell–cell and cell–stroma interactions, the tumor microenvironment, and therapeutic responsiveness. PDO models and drug-screening protocols have been described for several solid tumors and, more recently, for gliomas. Since PDOs can be developed in clinically relevant time frames and share many characteristics of parent tumors, they may enhance the ability to provide precision oncologic care for patients. This review explores the current literature on cancer organoids, highlighting the history of PDO development, organoid models of glioma, and potential clinical applications of PDOs. MDPI 2021-05-17 /pmc/articles/PMC8156513/ /pubmed/34067714 http://dx.doi.org/10.3390/jpm11050423 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pernik, Mark N. Bird, Cylaina E. Traylor, Jeffrey I. Shi, Diana D. Richardson, Timothy E. McBrayer, Samuel K. Abdullah, Kalil G. Patient-Derived Cancer Organoids for Precision Oncology Treatment |
title | Patient-Derived Cancer Organoids for Precision Oncology Treatment |
title_full | Patient-Derived Cancer Organoids for Precision Oncology Treatment |
title_fullStr | Patient-Derived Cancer Organoids for Precision Oncology Treatment |
title_full_unstemmed | Patient-Derived Cancer Organoids for Precision Oncology Treatment |
title_short | Patient-Derived Cancer Organoids for Precision Oncology Treatment |
title_sort | patient-derived cancer organoids for precision oncology treatment |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156513/ https://www.ncbi.nlm.nih.gov/pubmed/34067714 http://dx.doi.org/10.3390/jpm11050423 |
work_keys_str_mv | AT pernikmarkn patientderivedcancerorganoidsforprecisiononcologytreatment AT birdcylainae patientderivedcancerorganoidsforprecisiononcologytreatment AT traylorjeffreyi patientderivedcancerorganoidsforprecisiononcologytreatment AT shidianad patientderivedcancerorganoidsforprecisiononcologytreatment AT richardsontimothye patientderivedcancerorganoidsforprecisiononcologytreatment AT mcbrayersamuelk patientderivedcancerorganoidsforprecisiononcologytreatment AT abdullahkalilg patientderivedcancerorganoidsforprecisiononcologytreatment |